SCHEMBL16729397

SCHEMBL16729397

COCOc1cccc(NC(C)=O)c1CC[C@@H](C)O

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.43
RAB9A P51151 1/20 0.43
BRD4 O60885 1/20 0.41
TSHR P16473 2/20 0.41
SMN1; SMN2 Q16637 3/20 0.38
KMT2A Q03164 1/20 0.38
PTPN1 P18031 1/20 0.38
HSD17B10 Q99714 1/20 0.38
ALDH1A1 P00352 2/20 0.37
KDM4E B2RXH2 2/20 0.36
L3MBTL1 Q9Y468 2/20 0.36
MAPT P10636 2/20 0.36
POLB P06746 1/20 0.36
CYP2D6 P10635 1/20 0.36
MAPK1 P28482 1/20 0.35
MCL1 Q07820 1/20 0.35
ATM Q13315 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16717058 1.00 LMNA (0.43) LMNARAB9ABRD4TSHRSMN1; SMN2
SCHEMBL16717402 0.84 LMNA (0.39) LMNARAB9ABRD4TSHRSMN1; SMN2
SCHEMBL16717403 0.84 LMNA (0.39) LMNARAB9ABRD4TSHRSMN1; SMN2
SCHEMBL9900086 0.78 TYR (0.36) LMNATSHRPTPN1HSD17B10ALDH1A1
SCHEMBL16717617 0.77 PTPN1 (0.34) LMNASMN1; SMN2PTPN1ALDH1A1KDM4E
SCHEMBL16717622 0.77 PTPN1 (0.34) LMNASMN1; SMN2PTPN1ALDH1A1KDM4E
SCHEMBL16717445 0.77 LMNA (0.36) LMNASMN1; SMN2PTPN1ALDH1A1KDM4E
SCHEMBL9905670 0.74 ALDH1A1 (0.45) LMNARAB9ABRD4TSHRSMN1; SMN2
SCHEMBL27546271 0.69 BRD4 (0.61) LMNARAB9ABRD4TSHRSMN1; SMN2
SCHEMBL7892864 0.68 PTPN1 (0.50) LMNASMN1; SMN2PTPN1ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230061891-A1 TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS FORMA THERAPEUTICS, INC. 2023-03-02 US disclosed
US-11111229-B2 Tetrahydroquinoline compositions as BET bromodomain inhibitors FORMA THERAPEUTICS, INC. (US) 2021-09-07 US disclosed
EP-3799872-A1 TETRAHYDROQUINOLINE DERIVATIVES FOR USE AS BET INHIBITORS Forma Therapeutics, Inc. (US) 2021-04-07 EP disclosed
EP-3071203-B1 TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS FORMA THERAPEUTICS INC (US) 2020-12-23 EP disclosed
US-20200369642-A1 TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS FORMA THERAPEUTICS, INC. 2020-11-26 US disclosed
US-10611750-B2 Tetrahydroquinoline compositions as bet bromodomain inhibitors FORMA THERAPEUTICS, INC. (US) 2020-04-07 US disclosed
CN-110627770-A Tetrahydroquinoline compositions as BET bromodomain inhibitors 福马疗法公司 2019-12-31 CN disclosed
CN-105934246-B Tetrahydroquinoline compositions as BET bromodomain inhibitors 福马疗法公司 2019-10-22 CN disclosed
US-10336722-B2 Tetrahydroquinoline compositions as BET bromodomain inhibitors FORMA THERAPEUTICS, INC. (US) 2019-07-02 US disclosed
US-20190127347-A1 TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS FORMA THERAPEUTICS, INC. 2019-05-02 US disclosed
US-20160256448-A1 TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS FORMA THERAPEUTICS, INC. 2016-09-08 US disclosed
US-20160256448-A1 TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS FORMA THERAPEUTICS, INC. 2016-09-08 US disclosed
CN-105934246-A Tetrahydroquinoline compositions as BET bromodomain inhibitors 福马疗法公司 2016-09-07 CN disclosed
US-9388161-B2 Tetrahydroquinoline compositions as BET bromodomain inhibitors FORMA THERAPEUTICS, INC. (US) 2016-07-12 US disclosed
US-9388161-B2 Tetrahydroquinoline compositions as BET bromodomain inhibitors FORMA THERAPEUTICS, INC. (US) 2016-07-12 US disclosed
US-9388161-B2 Tetrahydroquinoline compositions as BET bromodomain inhibitors FORMA THERAPEUTICS, INC. (US) 2016-07-12 US disclosed
US-20150232445-A1 TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS FORMA THERAPEUTICS, INC. 2015-08-20 US disclosed
US-20150232445-A1 TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS FORMA THERAPEUTICS, INC. 2015-08-20 US disclosed
US-20150232445-A1 TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS FORMA THERAPEUTICS, INC. 2015-08-20 US disclosed
WO-2015074064-A2 TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS BAIR KENNETH W (US) 2015-05-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160256448-A1 TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS BRD4, BRD3, BRD1 LMNA 2940/4885RAB9A 1876/4885BRD4 1/4885
US-20190127347-A1 TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS BRD4, BRD3, BRD1 LMNA 2940/4885RAB9A 1876/4885BRD4 1/4885
US-10336722-B2 Tetrahydroquinoline compositions as BET bromodomain inhibitors BRD4, BRD3, BRD1 LMNA 2940/4885RAB9A 1876/4885BRD4 1/4885
US-11111229-B2 Tetrahydroquinoline compositions as BET bromodomain inhibitors BRD4, BRD3, BRD1 LMNA 2940/4885RAB9A 1876/4885BRD4 1/4885
US-20200369642-A1 TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS BRD4, BRD3, BRD1 LMNA 2940/4885RAB9A 1876/4885BRD4 1/4885
US-10611750-B2 Tetrahydroquinoline compositions as bet bromodomain inhibitors BRD4, BRD3, BRD1 LMNA 2940/4885RAB9A 1876/4885BRD4 1/4885
US-20150232445-A1 TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS BRD4, BRD3, BRD1 LMNA 2940/4885RAB9A 1876/4885BRD4 1/4885
US-20230061891-A1 TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS BRD4, BRD3, BRD1 LMNA 2940/4885RAB9A 1876/4885BRD4 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.